Sangamo Therapeutics (SGMOQ) Return on Capital Employed (2011 - 2025)

Sangamo Therapeutics' Return on Capital Employed history runs 15 years deep, the most recent figure standing at 382.12% for Q4 2025.

• On a quarterly basis, Return on Capital Employed fell 21068.0% year-over-year to 382.12% in Q4 2025; TTM through Dec 2025 was 382.12%, a 21068.0% decrease from a year earlier, with the FY2025 full-year figure at 317.18%, down 19859.0% from the prior year.
• Return on Capital Employed eased to 382.12% in Q4 2025 per SGMOQ's latest filing, from 253.69% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 16.95% in Q1 2021 and bottomed at 382.12% in Q4 2025.
• The 5-year median for Return on Capital Employed is 92.5% (2023), against an average of 134.92%.
• Across the five-year window, Return on Capital Employed sank 29154 bps in 2024 and jumped 21497 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 29.61% in 2021, then tumbled by 46 bps to 43.15% in 2022, then slumped by 339 bps to 189.26% in 2023, then grew by 9 bps to 171.44% in 2024, then plunged by 123 bps to 382.12% in 2025.
• Per Business Quant, the three latest SGMOQ Return on Capital Employed figures stand at 382.12% (Q4 2025), 253.69% (Q3 2025), and 142.17% (Q2 2025).